Biofrontera Inc.

BFRI

$1.52

-0.33%

2026-09-03 09:37:55 EDT-$0.01

Healthcare

Medical - Pharmaceuticals

NASDAQ

Active Trading

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. ...

Price Action of BFRI

$1.52

-0.33%-$0.01

High—

Low—

52W High-5.9%

Rel. vol—

Interval

Range3.7h

Volume—SMA5SMA10

—

Biofrontera Inc. (NASDAQ: BFRI) is a specialty biopharmaceutical company focused on dermatology and the commercialization of treatments built around photodynamic therapy (PDT). Headquartered in Woburn, Massachusetts, the company develops and markets products designed to treat dermatological conditions—particularly actinic keratosis, a pre-cancerous skin lesion. From a business perspective, Biofrontera’s model centers ...Biofrontera Inc. (NASDAQ: BFRI) is a specialty biopharmaceutical company focused on dermatology and the commercialization of treatments built around photodynamic therapy (PDT). Headquartered in Woburn, Massachusetts, the company develops and markets products designed to treat dermatological conditions—particularly actinic keratosis, a pre-cancerous skin lesion. From a business perspective, Biofrontera’s model centers on providing both a therapeutic active ingredient/topical product and the associated light-delivery technology required to perform PDT. This integrated approach can support treatment standardization for clinical use and helps align product adoption across dermatology care settings. The company operates in the medical-pharmaceutical space (Healthcare / Medical – Pharmaceuticals), emphasizing commercialization activities in the United States. Key products and platform elements include Ameluz (a topical formulation used in PDT for actinic keratosis) and the BF-RhodoLED / RhodoLED XL / RhodoLED lamp series used to deliver the light component of PDT. By bundling therapy and device aspects within its commercial portfolio, Biofrontera supports end-to-end patient treatment workflows rather than focusing solely on a single pharmaceutical or device. In terms of costs and bill-of-materials (BOM) considerations, PDT-based commercialization generally involves materials and production for the topical pharmaceutical component (e.g., formulation and packaging) along with device/manufacturing and components for the light-delivery lamps (e.g., optical/electronic elements, housings, and related accessories). While the specific cost structure and BOM quantities are not provided here, the company’s revenue drivers typically depend on product mix (topical therapy vs. lamp systems), distribution and fulfillment efficiency, and ongoing commercialization and market-access expenditures. Financially, the company’s TTM metrics provided reflect market valuation and operating performance indicators; however, detailed segment-level financials and management guidance are not included in the supplied data. Like many commercial-stage specialty biopharma firms, Biofrontera’s performance is influenced by product uptake, regulatory and clinical adoption cycles, sales and marketing efficiency, R&D investment levels, and working-capital management. Leadership is headed by CEO Hermann Lübbert, who is also recognized as a founder and founder/executive chairman figure in the company’s leadership history. With a relatively compact workforce (full-time employees provided as 72; company size cited in the 51–200 range), Biofrontera’s operations likely rely on a lean corporate structure while partnering with external stakeholders such as contract manufacturing organizations, distributors, and clinical/dermatology networks. Overall, Biofrontera aims to improve skin health outcomes by enabling effective PDT-based treatment in dermatology, leveraging its Ameluz plus RhodoLED lamp ecosystem to serve clinicians and patients seeking non-surgical options for actinic keratosis.ExpandCollapse

Founded

2015

Employees

CEO

Hermann Lübbert

Full Name

Biofrontera Inc.

Sector

Healthcare

Industry

Medical - Pharmaceuticals

ROE

-127.78%

Market Cap

$0.02B

Current Ratio

1.18

WACC

8.04%

ROIC

-66.61%

Contact Information

https://www.biofrontera-us.com

781 245 1325

660 Main Street, Woburn, MA 01801

Key Metrics of BFRI

Snapshot

Latest / TTM · 6 periods

Market Cap

$19.40M

ROCE

-32.3%

EV / EBITDA

-3.94x

+22.6% YoY

FCF Yield

-41.0%

+189.5% YoY

Cash Conversion Cycle

-172.9d

Current Ratio

1.18

Quick take

TTM —

No major risk flags in selected headline metrics.

Financial Highlights of BFRI

Profitability trend

Latest / TTM · 6 periods

Gross Margin

84.5%

Net Margin

-13.8%

P/E Ratio

-2.52x

n/a

Debt / Equity

1.26

n/a

Current Ratio

1.18

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of BFRI

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-0.22 · Revenue $8.25M · 1 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $0.23 · Revenue $15.80M · 1 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-0.39 · Revenue $46.15M · 1 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $-0.01 · Revenue $11.00M · 1 analysts

Recent history

Aug 13, 2026
Q2 FY2026 · Results reported
EPS $-0.05 · Revenue $12.00M
View filing
May 14, 2026
Q1 FY2026 · Results reported
EPS $-0.41 · Revenue $10.08M
View filing
Mar 19, 2026
FY2025 · Annual results
EPS $-0.90 · Revenue $41.70M
View filing
Nov 12, 2025
Q3 FY2025 · Results reported
EPS $-0.62 · Revenue $6.99M
View filing
Aug 13, 2025
Q2 FY2025 · Results reported
EPS $-0.57 · Revenue $9.03M
View filing
Mar 31, 2025
Q1 FY2025 · Results reported
EPS $-0.76 · Revenue $8.59M

Financial Statements of BFRI

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$41.7M	+11.8%	+19.0%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-10.5M	+40.7%	+87.3%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+78.7%	+56.9%	-2.3%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	-21.9%	+52.5%	+89.8%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	-25.3%	+46.9%	+89.3%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-13.4M	-29.4%	-2110.7%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	-32.0%	-15.7%	-1757.2%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	58.8%	-47.1%	-1.0%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	1.52x	-11.7%	-2.1%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$28.6M	+29.2%	-2.9%

Actual vs Estimate

A Dec 31Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-0.90 vs -1.39	+35.3%	-0.05 vs -0.10	+52.4%
Revenue Surprise	$41.7M vs $40.8M	+2.3%	$12.0M vs $9.5M	+26.3%

Insider Transactions of BFRI

Acquisitions (A)

Since Mar 4, 2026

Disposals (D)

Since Mar 4, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Jul 28, 2026	Luebbert Hermann	director, officer: CEO & Chairman	Common Stock	A	62,500	—
Jul 28, 2026	Luebbert Hermann	director, officer: CEO & Chairman	Restricted Stock Units	D	62,500	—
Jul 28, 2026	Leffler Eugene Frederick	officer: Chief Financial Officer	Common Stock	A	31,250	—
Jul 28, 2026	Leffler Eugene Frederick	officer: Chief Financial Officer	Restricted Stock Units	D	31,250	—
Mar 5, 2026	Luebbert Hermann	director, officer: CEO & Chairman	Common Stock	A	137,500	—

Earnings Call Transcript of BFRI

1 transcript segments

Q2 2026

Unknown Speaker

Operator: Welcome to the Biofrontera Second Quarter 2026 Financial Results and Business Update Conference Call. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference over to Ben Shamsian with Lytham Partners Investor Relations. Please go ahead. Behnam Shamsian: Good morning and welcome to Biofrontera Inc.'s Second Quarter 2026 Financial Results and Business Update Conference Call. Please note that certain information discussed during today's call by management is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. We caution listeners that Biofrontera's management will be making forward-looking statements and that actual results may differ materially from those stated or implied by these forward-looking statements due to the risks and uncertainties associated with the company's business. The forward-looking statements on today's call include statements regarding the company's full year 2026 revenue goals, the anticipated effects of the International Trade Commission orders and the company's remediation plan, the company's liquidity and the ability to continue as a going concern, the outcome of pending proceedings and the potential approval and launch of new indications for Ameluz. All risks and uncertainties are detailed and are qualified by the cautionary statements contained in Biofrontera's press release and SEC filings, including the company's quarterly reports on Form 10-Q for the quarter ended June 30, 2026, and the company's annual report on the Form 10-K for the year ended December 31, 2025. Also, this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast. Biofrontera undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call, except as required by law. During today's call, there will be references to certain non-GAAP financial measures. Biofrontera believes these measures provide useful information for investors, yet should not be considered as a substitute for GAAP, nor should they be viewed as a substitute for operating results determined in accordance with GAAP. A reconciliation of non-GAAP to GAAP results is included in the press release issued today and is available on the company's website at www.biofrontera-us.com under the Investor Relations section. Please note management will be referencing adjusted EBITDA, a non-GAAP financial measure defined as net loss excluding interest expense, net income taxes, depreciation, and amortization, and certain other non-recurring or non-cash items, including changes in fair value of warrant liabilities, panel remediation expense, and the related inventory write-down and stock-based compensation. With that said, I would now like to turn the call over to Hermann Luebbert, CEO, Chairman, and Founder of Biofrontera. Hermann, please proceed. Hermann Lubbert: Yes, …

Leadership Team of BFRI

7 executives

Name	Title	Compensation	Gender	Year Born	Status
Hermann Luebbert	Chief Executive Officer, President & Chairman	USD 687,482	—	1956	Active
Eugene Frederick Leffler	Chief Financial Officer	USD 461,333	Male	1985	Active
George Jones	Chief Commercial Officer	USD 275,184	Male	1973	Active
Daniel Hakansson	Senior Corporate Counsel	—	Male	—	Active
Jon Lyons	Vice President of Scientific & Medical Affairs	—	Male	—	Active
Erica F. Gates	VP of Finance & Principal Accounting Officer	—	Female	—	Active
Samantha Widdicombe	Senior Vice President of Sales & Strategic Accounts	—	Female	—	Active

Recent News of BFRI

Seeking Alpha8/13/2026Neutral

Biofrontera Inc. (BFRI) Q2 2026 Earnings Call Transcript

Zacks Investment Research8/13/2026Neutral

Biofrontera Inc. (BFRI) Reports Q2 Loss, Beats Revenue Estimates

Biofrontera Inc. (BFRI) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.57 per share a year ago.

GlobeNewsWire8/13/2026Neutral

Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth

WOBURN, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the quarter ended June 30, 2026.

GlobeNewsWire8/5/2026Neutral

Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026

WOBURN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a U.S. specialty dermatology company commercializing Ameluz® (aminolevulinic acid hydrochloride) Gel, 10% with the BF-RhodoLED® lamp for photodynamic therapy (PDT) of actinic keratosis, today announced that it will report financial results for the second quarter ended June 30, 2026 before the market opens on Thursday, August 13, 2026.

Seeking Alpha6/11/2026Neutral

Biofrontera Inc. (BFRI) Shareholder/Analyst Call Prepared Remarks Transcript

Historical Employee Count of BFRI

Current

Change

-21.74%

Minimum

Maximum

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	72	10-K	Mar 19, 2026	View
Dec 31, 2024	92	10-K	Mar 20, 2025	View
Dec 31, 2023	83	10-K	Mar 15, 2024	View
Dec 31, 2022	81	10-K	Mar 13, 2023	View
Dec 31, 2021	69	10-K	Apr 11, 2022	View

Related stocksMedical - Pharmaceuticals

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Biofrontera Inc.